Stifel Nicolaus Boosts Kinnate Biopharma Price Target to 2.59
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
About 61% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
Kinnate |
Kinnate Biopharma had its price objective raised by equities researchers at Stifel Nicolaus from 1.50 to 2.59 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a hold rating on the stock. Stifel Nicolaus price target would suggest a potential upside of 3.60 percent from
Read at thelincolnianonline.com
 |
Kinnate Biopharma Fundamental Analysis
We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Kinnate Biopharma is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Kinnate Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.
Peers
Kinnate Biopharma Related Equities
| KRON | Kronos Bio | 2.17 | ||||
| BOLT | Bolt Biotherapeutics | 1.96 | ||||
| PASG | Passage Bio | 1.54 | ||||
| LRMR | Larimar Therapeutics | 1.00 | ||||
| STOK | Stoke Therapeutics | 1.60 | ||||
| SLRN | ACELYRIN, INC | 2.11 | ||||
| GLUE | Monte Rosa | 2.22 | ||||
| KROS | Keros Therapeutics | 2.32 | ||||
| KZR | Kezar Life | 2.92 | ||||
| ERAS | Erasca | 3.05 | ||||
| EWTX | Edgewise Therapeutics | 3.10 | ||||
| WINT | Windtree Therapeutics | 3.13 | ||||
| GBIO | Generation Bio | 3.60 | ||||
| DSGN | Design Therapeutics | 3.70 | ||||
| IPSC | Century Therapeutics | 3.70 | ||||
| CCCC | C4 Therapeutics | 5.25 | ||||
| PALI | Palisade Bio | 5.65 | ||||
| SRZN | Surrozen | 5.95 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |